Phase 2 N=11 Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
Anemia, Aplastic · Red-Cell Aplasia, Pure · Anemia, Diamond-Blackfan
Primary: Response to Rituximab — 0; 2; 9 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag
Anemia, Diamond-Blackfan
Primary: Participants That Responded to Eltrombopag — 1; 14 Participants
Phase 2 N=55 Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia
Diamond Blackfan Anemia · Blackfan Diamond Syndrome · DBA
Primary: Response to Leucine in Transfusion Dependent Patients With Diamond Blackfan Anemia — 2; 5; 36; 0 Participants
Phase 2 N=14 Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
Anemia · Primary Myelofibrosis · Secondary Myelofibrosis
Primary: Best Overall Response Rate as Determined by International Working Group Criteria — 28.6 percentage of patients with CR, PR or CI
Phase 2 N=6 Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs
Sickle Cell Disease · Thalassemia · Diamond-Blackfan Anemia
Primary: Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT) — 3 Participants
Phase 2 N=102 Darbepoetin Administration to Preterm Infants
Infant, Newborn
Primary: Number of Transfusions During Hospitalization — 1.2; 1.2; 2.4 number of transfusions
Phase 3 N=147 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
MDS
Primary: Percentage of Participants With at Least One Red Blood Cell (RBC) Transfusion During the Double-blind Treatment Period — 59.2; 36.1 percentage of participants — p=0.008
Phase 2 N=6 Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia
Thalassemia
Primary: Number of Evaluable Patients With an Increase From Baseline in Hemoglobin (Hb) of ≥1.5 g/dL — 2 participants
N/A N=61 Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
Dyskeratosis Congenita · Aplastic Anemia
Primary: Incidence of Neutrophil Engraftment — 100; 100; 96; 100 Percentage of participants
Phase 3 N=594 Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Primary: Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to…
Phase 2 N=27 Danazol for Genetic Bone Marrow and Lung Disorders
Aplastic Anemia
Primary: Number of Patients Having Attenuation of Accelerated Telomere Attrition — 12 Participants
Phase 3 N=229 A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Myelodysplastic Syndromes
Primary: Percentage Of Participants Who Achieved Red Blood Cell Transfusion Independence (RBC-TI) ≥ 8 Weeks From Week 1 to Week 24 — 37.91; 13.16 Percent of Participants…
Phase 2 N=34 Eltrombopag for Moderate Aplastic Anemia
Moderate Aplastic Anemia · Unilineage Bone Marrow Failure Disorders
Primary: Proportion of Drug Responders — 17 Participants
N/A N=441 Anemia Management in Chronic Kidney Disease Not on Dialysis Patients After the European Renal Best Practice (ERBP) Working Group Recommendations
ANEMIA
Primary: % Patients Achieving Target Hemoglobin Levels — 42.5; 35.3 percentage of participants
Phase 2 N=45 Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
Aplastic Anemia · Leukemia · Myelodysplastic Syndrome
Primary: Successful Neutrophil Engraftment — 44; 1 Participants
Phase 3 N=4 Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
Anaemia
Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 1; 0 Participants
Phase 2 N=52 Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia
Adult Myelodysplastic Syndrome · Anemia · Chronic Myelomonocytic Leukemia
Primary: Number of Patients Demonstrating Overall Hematologic Improvement (HI) — 6; 5; 7 Participants
Phase 2 N=17 Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Leukemia · Leukemia, Myeloid · Monocytic Leukemia
Primary: Clinical Response: Hematological Improvement - Erythroid (HI-E) — 0; 0 participants
Phase 2 N=100 Practical Anemia Bundle for SusTained Blood Recovery
Anemia · Critical Illness
Primary: Hemoglobin Concentrations — 11.5; 12.2 g/dL — p=0.02
N/A N=62 Intelligent Control Approach to Anemia Management
End-Stage Renal Disease
Primary: Percent Hb 10-12 g/dL — 61.9; 72.5 Percent
Phase 2 N=14 Pilot Study of Metformin for Patients With Fanconi Anemia
Fanconi Anemia
Primary: Hematologic Response — 4 Participants
Phase 3 N=490 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
Anemia · Leukemia · Lymphoma
Primary: Hematopoietic Response Rate Defined as the Number of Participants Who Exhibit a Hematopoietic Response — 114; 109; 106; 50 Participants — p=0.39
Phase 3 N=239 A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q
Anemia
Primary: Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC) — 2.5; 26.9…
N/A N=146 Analyses of Anemia in Very Low Birth Weight (VLBW) Infants.
Very Preterm Maturity of Infant · The Risk Factors for Improving the Prognosis of VLBW Infants
Primary: The Incidence of Early Onset Sepsis in VLBW Infants With AOP. — 18; 34; 7; 42 Participants
Phase 2 N=15 Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)
Anaemia
Primary: Percentage of Fractional Oral Iron Absorption Following Treatment With Daprodustat and rhEPO — 20.64; 20.62 Percentage (%) of iron absorbed — p=0.9971
N/A N=29 Calcium Absorption in Patients With Rothmund-Thomson Syndrome
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
Phase 3 N=836 Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
Anemia · End Stage Renal Disease (ESRD)
Primary: Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)] — 0.428; 0.193 g/dL — p=<0.001
Phase 4 N=184 Treatment Response in Dialysis Anaemia
Anaemia · Haemodialysis
Primary: Haemoglobin Increase of Greater or Equal to 5g/l Following Receipt of Treatment — 53; 61 Participants
Phase 2 N=30 Sirolimus for Autoimmune Disease of Blood Cells
Autoimmune Pancytopenia · Autoimmune Lymphoproliferative Syndrome (ALPS) · Evans Syndrome
Primary: Number of Participants With Grade 3 and 4 Toxicities of Administration of Oral Sirolimus — 1 participants
Early Phase 1 N=5 RHD Genotype Matched Red Cells for Anti-D
Sickle Cell Disease · Anti-D Antibodies
Primary: Anti-D Recurrence — 0; 5 Participants